Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• ATIP3-deficient breast cancers are aggressive with poor prognosis and limited treatment options.
• Identifying novel therapeutic targets for this subset is critical.

Purpose of the Study:

• To screen cell cycle kinase inhibitors for novel therapeutic targets in ATIP3-deficient breast cancers.
• To investigate the mechanisms underlying the sensitivity of these cancers to specific inhibitors.

Main Methods:

• Screening of cell cycle kinase inhibitors.
• Analysis of mitotic aberrations, centromere protein detachment, and chromosome pulverization.
• Investigation of replication stress, DNA damage, and CDK1 activation.
• Identification of DNA2 helicase/nuclease involvement.

Main Results:

• ATIP3 deficiency sensitizes breast cancer cells to WEE1 inhibition.
• WEE1 inhibition leads to aberrant mitoses, including chromosome pulverization.
• This phenotype is linked to replication stress, DNA damage, and premature CDK1 activation.
• DNA2 helicase/nuclease is identified as a key mediator of chromosome pulverization.

Conclusions:

• Heightened sensitivity of ATIP3-deficient cells to WEE1 inhibition supports clinical trials of WEE1-targeted therapies.
• Combination therapy with WEE1 and PKMYT1 inhibitors enhances efficacy.
• This offers a personalized treatment strategy for ATIP3-deficient breast cancers.